


Claims

1. A compound of formula (I)



in which

according to embodiment a):

V, W and Z each represent CH, and Y represents CR^2 ,

or

V, W and Y of each represent CH, and Z represents CR^2 ,

or

V and W each represent CH, and Y and Z independently of each other represent CR^2 ,

or,

V represents N, and W represents CH or CR^2 , and Y and Z each represent CH,

R^1 represents a methyl group,

R^2 represents, independently of each other, fluorine, chlorine or a group selected from:

methyl, methoxy, $-\text{N}(\text{H})\text{C}(=\text{O})-\text{CH}_3$, and $-\text{N}(\text{H})\text{C}(=\text{O})$ -cyclopropyl,

R^3 represents a $-(\text{CH}_2)_2\text{OH}$ group, or

according to embodiment b):

V, W, Y and Z independently of each other represent CH or CR^2 , wherein one of V, W, Y and Z represents CR^2

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

R¹ represents a C₁-C₃-alkyl group,

R² represents, independently of each other, halogen or a group selected from:
C₁-C₃-alkyl, C₃-C₄-cycloalkyl, C₁-C₃-haloalkyl, C₁-C₃-alkoxy,
and -N(H)C(=O)-(C₁-C₃-alkyl),

R³ represents R⁴,

R⁴ represents -(CH₂)₂-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,

R⁵ and R⁷ independently of each other represent a group selected from:
-CH₃ (alanine), and -(CH₂)₄NH₂ (lysine),

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

2. The compound of formula (I) according to claim 1,
wherein

according to embodiment a):

V, W and Z each represent CH, and Y represents CR²,

or

V, W and Y of each represent CH, and Z represents CR²,

or

V and W each represent CH, and Y and Z independently of each other represent CR²,

or,

V represents N, and W represents CH or CR², and Y and Z each represent CH,

R¹ represents a methyl group,

R² represents, independently of each other, fluorine, chlorine or a group selected
from:

methyl, methoxy, -N(H)C(=O)-CH₃, and -N(H)C(=O)-cyclopropyl,

R³ represents a -(CH₂)₂OH group, or

according to embodiment b):

V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W, Y and Z represents CR²

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

R¹ represents a methyl group,

R² represents, independently of each other, fluorine, chlorine or a group selected from: methyl, cyclopropyl, difluoromethyl, methoxy, and -N(H)C(=O)-CH₃,

R³ represents R⁴,

R⁴ represents -(CH₂)₂-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,

R⁵ represents -CH₃ (alanine),

R⁷ represents -(CH₂)₄NH₂ (lysine),

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

3. The compound of formula (I) according to claim 1 or 2, wherein

V, W and Z each represent CH, and Y represents CR²,

or

V, W and Y of each represent CH, and Z represents CR²,

or

V and W each represent CH, and Y and Z independently of each other represent CR²,

or,

V represents N, and W represents CH or CR², and Y and Z each represent CH,

R¹ represents a methyl group,

R^2 represents, independently of each other, fluorine, chlorine or a group selected from:
methyl, methoxy, $-N(H)C(=O)-CH_3$,
and $-N(H)C(=O)-cyclopropyl$,

R^3 represents a $-(CH_2)_2OH$ group,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

4. A compound, which is selected from the group consisting of:

2-{4-[(3-{4-[(3-chloropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}acetamide ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{4-[(3-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-5-ol
2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{4-[(5-fluoro-2-methylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-[3,5-difluoro-4-({3-[5-methoxy-4-(pyrimidin-4-ylamino)pyrimidin-2-yl]-1*H*-indazol-1-yl)methyl]phenoxy]ethanol
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate,

N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}cyclopropanecarboxamide ,

1-cyclopropyl-3-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}urea ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(5-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,

3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}propan-1-ol ,

(2*R*)-3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,

N-[4-[(2-{1-(2,6-difluoro-4-[(2*R*)-3-hydroxy-2-methylpropyl]oxy}benzyl)-1*H*-indazol-3-yl]-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl]acetamide ,

(2*R*)-3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,

2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl D-lysyl-L-alaninate, salt with trifluoroacetic acid ,

2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl D-lysyl-L-alaninate ,

2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid , and

2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate with trifluoroacetic acid ,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

5. A compound according to claim 4, which is selected from the group consisting of:

2-{4-[(3-{4-[(3-chloropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-

yl)methyl]-3,5-difluorophenoxy}ethanol ,
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}acetamide ,
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 2-{3,5-difluoro-4-[(3-{4-[(3-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-5-ol
 2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 2-{3,5-difluoro-4-[(3-{4-[(5-fluoro-2-methylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 2-[3,5-difluoro-4-[(3-[5-methoxy-4-(pyrimidin-4-ylamino)pyrimidin-2-yl]-1*H*-indazol-1-yl)methyl]phenoxy]ethanol
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxy-pyrimidin-4-yl)amino]pyridin-2-yl}cyclopropanecarboxamide ,
 1-cyclopropyl-3-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}urea ,
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(5-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
 3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}propan-1-ol ,

(2R)-3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,
 (2R)-3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy}-2-methylpropan-1-ol ,
 N-[4-({2-[1-(2,6-difluoro-4-[(2R)-3-hydroxy-2-methylpropyl]oxy}benzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl]acetamide ,
 (2R)-3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,
 2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethyl D-lysyl-L-alaninate, salt with trifluoroacetic acid ,
 and
 2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

6. A compound according to claim 1, which is 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethanol, or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

7. A compound according to claim 1, which is 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethanol, or an N-oxide, or a pharmaceutically acceptable salt of said compound, or a salt of said N-oxide.

8. A compound according to claim 1, which is 2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethanol.

9. A compound of general formula (I) according to any of claims 1 to 8 for use in the treatment or prophylaxis of a disease.

10. Use of a compound of general formula (I) according to any of claims 1 to 8 in the manufacture of a medicament for the treatment or prophylaxis of a disease, whereby the disease is a hyperproliferative disease and/or a disorder responsive to induction of cell death,

whereby the hyperproliferative disease and/or disorder responsive to induction of cell death is a haematological tumour, a solid tumours and/or metastases thereof.


11. Use of a compound of general formula (I) according to claim 10, whereby the hyperproliferative disease is cervical cancer.

12. A pharmaceutical composition comprising at least one compound of general formula (I) according to any of claims 1 to 8, together with at least one pharmaceutically acceptable carrier or auxiliary.

13. Use of a composition according to claim 12 in the manufacture of a medicament for the treatment of a haematological tumour, a solid tumour and/or metastases thereof.


14. A combination comprising one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 8, and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.

15. A compound of formula:




in which R¹, V, W, Y and Z are as defined in any one of claims 1 to 8, and R⁹ represents a methyl- or an ethyl group or a *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, triethylsilyl, triisopropylsilyl or tetrahydropyranyl group.

16. The use of a compound:



for the preparation of a compound of general formula:



in which R^1 , V, W, Y and Z are as defined in any one of claims 1 to 8.